# RemeGen

Source: https://onco.cc/companies/remegen/  
OnCo record `remegen` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

RemeGen developed disitamab vedotin, China's first domestic ADC.

## Summary

RemeGen, based in Yantai and listed in Hong Kong as 9995.HK, developed disitamab vedotin, China's first domestically developed antibody-drug conjugate. Disitamab vedotin, also known as RC48, targets HER2 and is used in gastric and urothelial cancer, and the company's other main product is telitacicept for autoimmune disease. OnCo links it to gastric and HER2-positive breast cancer, to the disitamab vedotin drug record and to Peking University Cancer Hospital. Whether a HER2 ADC with an older payload can find a durable niche as newer HER2 ADCs spread is the open question. Disitamab vedotin has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Yantai
- Type: biotech
- Website: https://www.remegen.com
- Ticker: 9995.HK

## Sources

- Official website: https://www.remegen.com

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- drugs: [Disitamab vedotin](https://onco.cc/drugs/disitamab-vedotin/), [RC118-ADC](https://onco.cc/drugs/rc118-adc/), [RC148](https://onco.cc/drugs/rc148/)
- trials: [A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors](https://onco.cc/trials/nct07105215/), [A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Adv](https://onco.cc/trials/nct06962865/), [A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer](https://onco.cc/trials/nct07462143/), [A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.](https://onco.cc/trials/nct07315750/), [A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors](https://onco.cc/trials/nct06157892/), [A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors](https://onco.cc/trials/nct05205850/), [A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors](https://onco.cc/trials/nct06038396/), [A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors](https://onco.cc/trials/nct06016062/), [A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer](https://onco.cc/trials/nct05980481/), [A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent o](https://onco.cc/trials/nct06155396/), [A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation](https://onco.cc/trials/nct05745740/), [A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma](https://onco.cc/trials/nct05302284/), [Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2](https://onco.cc/trials/nct05911295/), [DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy](https://onco.cc/trials/nct06221748/), [DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer](https://onco.cc/trials/nct06178159/), [Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer](https://onco.cc/trials/nct06642545/), [Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer](https://onco.cc/trials/nct06227117/), [Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.](https://onco.cc/trials/nct06155383/), [Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Act](https://onco.cc/trials/nct07829549/), [RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)](https://onco.cc/trials/sqnsclc/), [To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer](https://onco.cc/trials/nct06389006/), [To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2](https://onco.cc/trials/nct06378242/)
- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- institutions: [Peking University Cancer Hospital](https://onco.cc/institutions/pku-cancer-hospital/)

---
JSON: https://onco.cc/api/v1/entities/remegen.json